Canopus BioPharma sees positive results in Ebola treatment study

Canopus BioPharma, Inc. recently released positive results from a study that tested the effectiveness of a prescription drug treatment for Ebola called CB008.

The in-vitro live Ebola virus study, conducted at Texas Biomedical Research Institute at San Antonio, tested the treatment’s ability to stope the Ebola virus from spreading. It is an orally administered drug that specifically focuses on preventing the Zaire strain of the Ebola virus. 

The FDA originally approved CB008 in the 1980s. It was used for other medical purposes at the time, but now its effectiveness may prove helpful in treating Ebola.

Canopus BioPharma researchers hope to test CB008 in a primate study soon. After this phase of the study is completed, the drug will be sent to West Africa to be tested in a human Ebola clinical trial if its found to be successful in primates.

“What we have shown by the use of CB008 in tissue culture is how vulnerable these Ebola viruses are when you interfere with their mechanism of creating havoc both to epithelial cells and to the immune system" Dr. Leo Shanahan-Prendergast, a researcher at Canopus BioPharma, said.

There are several other prescription drugs related to CB008 that also may inhibit Ebola and prevent Hemorrhagic syndrome.

Organizations in this Story


Want to get notified whenever we write about PharmiWeb ?
Next time we write about PharmiWeb, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.